心衰门诊常规评估患者报告健康状态对临床结局的影响:PRO-HF试验
PRO-HF试验是一项开放标签、平行、患者层面随机临床试验,纳入1248例心衰患者,比较常规PRO评估与常规 care 对1年患者报告生活质量的影响。结果显示两组KCCQ-12总体摘要评分无显著差异(基线校正均差0.2,95%CI -1.7至2.0,P=0.85),且死亡率、住院、急诊就诊、药物治疗、随访和检查率均无显著差异。
要点
- 心衰门诊常规使用KCCQ-12未改善1年生活质量或临床结局。
- 两组KCCQ-12评分变化无显著差异,亚组分析一致。
- 事后分析提示基线KCCQ-12 60-80的患者可能获益,需进一步验证。
核心结论
- 心衰门诊常规PRO评估未影响患者报告的生活质量或其他临床结局。
研究设计与样本
- 开放标签、平行、患者层面随机临床试验,于2021年8月30日至2022年6月30日在学术心衰门诊进行,随访1年,纳入1248例参与者,随机分为PRO评估组(n=624)和常规 care 组(n=624),涉及17名临床医生。
主要发现
- 主要结局KCCQ-12总体摘要评分在随机化后12至15个月:PRO组中位数87.5(IQR 68.8-96.9),常规 care 组87.6(IQR 69.7-96.9),基线校正均差0.2(95%CI -1.7至2.0;P=0.85)。
- 最终KCCQ-12可用率:PRO组87.9%,常规 care 组85.1%(P=0.16)。
- 预设亚组结果一致;事后分析显示基线KCCQ-12 OSS 60-80的参与者有显著交互作用,但症状更轻或更重的参与者未见获益。
- 1年死亡率、住院、急诊就诊、药物治疗、门诊随访或检查率两组间无显著差异。
临床怎么用
- 常规在Heart Failure门诊使用KCCQ-12并未改善患者报告的生活质量或临床结局,不支持将其作为改善这些结局的常规策略。
- 可考虑探索其他策略和设置将PROs嵌入常规临床 care。
局限性
- 开放标签设计可能引入偏倚。
- 事后分析提示的亚组获益需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year. METHODS: The PRO-HF trial (Patient-Reported Outcome Measurement in Heart Failure Clinic) was an open-label, parallel, patient-level randomized clinical trial of routine PRO assessment or usual care at an academic HF clinic between August 30, 2021, and June 30, 2022, with 1 year of follow-up. In the PRO assessment arm, participants completed the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) at each HF clinic visit, and results were shared with their treating clinician. The usual care arm completed the KCCQ-12 at randomization and 1 year later, which was not shared with the treating clinician. The primary outcome was the KCCQ-12 overall summary score (OSS) between 12 and 15 months after randomization. Secondary outcomes included domains of the KCCQ-12, hospitalization and emergency department visit rates, HF medication therapy, clinic visit frequency, and testing rates. RESULTS: Across 17 clinicians, 1248 participants were enrolled and randomized to PRO assessment (n=624) or usual care (n=624). The median age was 63.9 years (interquartile range [IQR], 51.8-72.8), 38.9% were women, and the median baseline KCCQ-12 OSS was 82.3 (IQR, 58.3-94.8). Final KCCQ-12 (available in 87.9% of the PRO arm and 85.1% in usual care; P=0.16) median OSS were 87.5 (IQR, 68.8-96.9) in the PRO arm and 87.6 (IQR, 69.7-96.9) in the usual care arm with a baseline-adjusted mean difference of 0.2 ([95% CI, -1.7 to 2.0]; P=0.85). The results were consistent across prespecified subgroups. A post hoc analysis demonstrated a significant interaction with greater benefit among participants with a baseline KCCQ-12 OSS of 60 to 80 but not in less or more symptomatic participants. No significant differences were found in 1-year mortality, hospitalizations, emergency department visits, medication therapy, clinic follow-up, or testing rates between arms. CONCLUSIONS: Routine PRO assessment in HF clinic visits did not impact patient-reported quality of life or other clinical outcomes. Alternate strategies and settings for embedding PROs into routine clinical care should be tested. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04164004.
引用
- Sandhu, Calma, Skye, et al. Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic: The PRO-HF Trial. Circulation. 2024. PMID: 38583147. doi:10.1161/CIRCULATIONAHA.124.069624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。